In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant weight loss in obese mice but also slashed breast cancer tumor growth. The research, presented at ENDO 2025, links body fat reduction to better cancer outcomes, suggesting that these next-generation weight-loss drugs might offer unexpected benefits beyond metabolic health. With traditional dieting often falling short, this dual-action approach could reshape how doctors tackle obesity-related cancers.
from Top Health News -- ScienceDaily https://ift.tt/xUASW1X
the news of the day, for today, top news of today, world news today live, top local news, top news stories of the day, top news today in the world, news today nyc, top news today local,
Subscribe to:
Post Comments (Atom)
New Alzheimer's drug repairs DNA damage and reduces brain inflammation
A drug originally developed for spinal cord injury may offer a fresh approach to treating Alzheimer’s disease. In mouse studies, KCL-286 rep...
No comments:
Post a Comment